Literature DB >> 1944915

High-dose oral baclofen: experience in patients with multiple sclerosis.

C R Smith1, N G LaRocca, B S Giesser, L C Scheinberg.   

Abstract

We reviewed a 10% random sample of charts from an outpatient clinic for multiple sclerosis to determine the frequency with which baclofen was prescribed for spasticity in high doses (greater than 80 mg/d). About 20% of patients had taken high-dose baclofen, and 15% were still receiving a high dose. Taking a high dose was not associated with discontinuing treatment.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1944915     DOI： 10.1212/wnl.41.11.1829

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  7 in total

1.  A Longitudinal Study of the Neurologic Safety of Acute Baclofen Use After Spinal Cord Injury.

Authors:  Jacquelyn J Cragg; Bobo Tong; Catherine R Jutzeler; Freda M Warner; Neil Cashman; Fred Geisler; John L K Kramer
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

2.  Cost-effectiveness comparison of tizanidine and baclofen in the management of spasticity.

Authors:  David N Rushton; Adam C Lloyd; Pippa M Anderson
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 3.  A benefit-risk assessment of baclofen in severe spinal spasticity.

Authors:  Alessandro Dario; Giustino Tomei
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

4.  Phosphinic acid derivatives as baclofen agonists and antagonists in the mammalian spinal cord: an in vivo study.

Authors:  G Lacey; D R Curtis
Journal:  Exp Brain Res       Date:  1994       Impact factor: 1.972

Review 5.  Drugs used to treat spasticity.

Authors:  M Kita; D E Goodkin
Journal:  Drugs       Date:  2000-03       Impact factor: 11.431

Review 6.  Rational approaches for the design of various GABA modulators and their clinical progression.

Authors:  Kavita Bhagat; Jatinder V Singh; Piyusha P Pagare; Nitish Kumar; Anchal Sharma; Gurinder Kaur; Nihar Kinarivala; Srinivasa Gandu; Harbinder Singh; Sahil Sharma; Preet Mohinder S Bedi
Journal:  Mol Divers       Date:  2020-03-13       Impact factor: 2.943

Review 7.  GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence.

Authors:  Roberta Agabio; Giancarlo Colombo
Journal:  Front Neurosci       Date:  2014-06-06       Impact factor: 4.677
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.